Enanta Pharmaceuticals Inc ENTA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:21 PM EDT
14.98quote price arrow up+1.07 (+7.71%)
Volume
55,238
52 week range
8.08 - 37.14
Loading...
  • Open14.34
  • Day High15.13
  • Day Low14.21
  • Prev Close13.91
  • 52 Week High37.14
  • 52 Week High Date05/05/23
  • 52 Week Low8.08
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap316.974M
  • Shares Out21.16M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.59
  • YTD % Change59.51

KEY STATS

  • Open14.34
  • Day High15.13
  • Day Low14.21
  • Prev Close13.91
  • 52 Week High37.14
  • 52 Week High Date05/05/23
  • 52 Week Low8.08
  • 52 Week Low Date11/10/23
  • Market Cap316.974M
  • Shares Out21.16M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.59
  • YTD % Change59.51

RATIOS/PROFITABILITY

  • EPS (TTM)-6.56
  • P/E (TTM)-2.28
  • Fwd P/E (NTM)-2.91
  • EBITDA (TTM)-139.578M
  • ROE (TTM)-56.11%
  • Revenue (TTM)73.622M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-187.77%
  • Debt To Equity (MRQ)0.74%

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Enanta Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic...
Bruce Carter Ph.D.
Independent Non-Executive Chairman of the Board
Jay Luly Ph.D.
President, Chief Executive Officer, Director
Paul Mellett Jr.
Chief Financial and Administrative Officer
Address
500 Arsenal Street
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
ADCT
ADC Therapeutics SA
4.92+0.19+4.02%
NKTR
Nektar Therapeutics
1.61-0.05-3.29%
PSTX
Poseida Therapeutics Inc
2.88+0.09+3.23%
GTHX
G1 Therapeutics Inc
4.55+0.11+2.48%
EDIT
Editas Medicine Inc
5.67+0.05+0.98%